banner

Sunday, November 10, 2013

Movie review:Krrish 3

Krrish 3 box office record

Cast: Hrithik Roshan, Priyanka Chopra, Vivek Oberoi, Kangana Ranaut
Director: Rakesh Roshan

Bloggermans Rating : 6.9/10 



Superhero sci-fi drama "Krrish 3" is flying high at the box office with both multiplexes and single screen theatres getting overwhelming footfalls on the opening day Friday across the country. The Hrithik Roshan-starrer will be a blockbuster, predict experts.
Released Friday, "Krrish 3" is equipped with a spectacular range of special effects and extravagant action sequences. Hrithik returns as the superhero with the film that is the third instalment in the franchise that began with "Koi... Mil Gaya" in 2003.
Deepak Sharma, COO of PVR Pictures, says that the film has got "great opening and it's going to be a blockbuster".
"The advance booking is as good as it was for 'Chennai Express' and opened like that all across India. Once holiday starts it will do amazing business. It can be in the league of Rs.200 crore. Going by morning show, it's looking good," Sharma told IANS.
Vivek Oberoi plays Kaal, the villain, in the movie directed and produced by Rakesh Roshan. It also features Kangana Ranaut and Priyanka Chopra.
Reportedly made on a budget of about Rs.100-Rs.150 crore, "Krrish 3" hit approximately 3,500 screens Friday, said a source.
Red Chillies VFX, a subdivision of Shah Rukh's motion picture production banner Red Chillies Entertainment, worked on the special effects worth Rs.26 crore for "Krrish 3".
Apart from the metro cities, the movie got an overwhelming response to the morning shows in Uttar Pradesh and Rajasthan too, said trade analyst Taran Adarsh tweeted.
"The pre-Diwali period is always considered dull by the industry. But a film like 'Krrish 3' can change the mindset," Taran tweeted.
Another trade pundit Komal Nahta posted similar opinion on the microblogging site.
"'Krrish 3' opening in Bihar circuit crazy. Most cinemas report, all shows full in advance. Such madness rarely seen. And this is pre-Diwali!," posted Nahta.
R.K. Mehrotra, general manager, Delite cinemas, said that on the first day mostly children accompanied by their parents came to watch the film.
"The opening was extraordinary. It’s housefull till Wednesday. Kids were seen applauding while watching it. The special effects and action sequences are wonderful. ‘Krrish’ is at par with Hollywood films,” said Mehrotra.
"Krrish 3" has hit about 700 screens down south and trade analyst Trinath said "Krrish" did good business in Tamil Nadu when it released in 2006.
"It was an instant hit in the state, collecting approximately Rs.1.2 crore in first two weeks. It was huge for a Hindi film and it was received very well. 'Krrish 3' was approximately released in about 700 screens in the south," Trinath said.
"In Andhra Pradesh, since there are no Diwali releases, the film released in over 300 screens. Despite mixed reviews from critics, audiences are watching it because it's the only big theatre in cinemas this weekend," he added.
'Krrish 3' is a superhero film. It is also a throwback to the creaky family entertainers Bollywood used to make. The hero has special powers, sure, but also a loving daddy, a lovely wifey, an attractive moll and a villain with severe daddy issues. Only a pet poodle or parrot is missing.
Superheroes have been around in Hindi cinema for decades, but huge technology jumps have made 'Krrish 3' the slickest of them all, special effects-wise. The rest of it is marred by tackiness. When Krrish is doing his derring-do stunts, we watch, even if we've seen Superman do this 30 years ago. But when he delivers maudlin dialogue about fathers and mothers and bravery, we are pulled back to the ground with a thud, with the superhero the Roshans made.
Hrithik is the perfect choice amongst the Bollywood superstar lot to do this role. With his superbly articulated chest, each muscle moving and shiny and oiled, Krrish doesn't even need a mask and a cape. But the ensemble is eye-catching, and we ignore his immaculately-styled long hair, flying in the wind, when he is whizzing about rescuing little boys. Roshan Jr is as likeable and earnest as he usually is, but can't rise above the mothballed treatment. Roshan Sr, who has written and directed, should have given the superhero more to do.
But he gets stuck in bringing the backstory forward. The soppy but sweet `Koi Mil Gaya's ( 2003) socially challenged but brilliant Rohit begets Krishna, who finds his super-powers in 'Krrish' ( 2006). Both the ageing Rohit and Krishna star in `'Krrish 3', and both roles are played by Hrithik. Priyanka, playing Krishna's TV reporter wife, has to look on admiringly as Hrithik does his standard dance number. He is still as dextrous, but the dancing has no zing, and the songs are terrible.
All is hunky dory, with Krrish doing his superhero stuff, rescuing a damaged aircraft ( there are no seat belts around the screaming passengers : should we care, or does anything go if it is a superhero film? ). And then Kaal ( Oberoi, kitted out in pale pancake and snarls), with the help of his coldly beautiful creation Kaya ( Ranaut, fancy-plaited and slitty-eyed) and a few other `human-aliens', rears up in his den in some snowy mountains in an unspecified spot. And begins his plans of decimating the human race.

The team should be appreciated for the efforts taken, I would say a great step forward, people who say the movie is real bad says that because all these sci-fi films directly get compared with high  budget hollywood movies. All the graphics of Krrish 3 are home gown and have done a pretty decent job.


Songs are awful though, but Hrithik makes up a lot with his awesome dancing moves and Kangana Ranaut sure looks hot and has done justice to her  role. Bollywood is new to this kind of genre (with high technology and graphics all around )and Rakesh Roshan and crew have done justice to the attempt made ,(even though a lot of flaws could have been avoided with a bit more care )and have opened the door for more movies to follow 

Thursday, November 7, 2013

MARKSANS PHARMA MULTIBAGGER



MARKSANS PHARMA A REAL TURNAROUND COMPANY





Our economy and stock market is going through a rough patch  for the past many months ( not the indices) .Reasons may vary from weak government,policy paralysis,higher inflation,current account deficit ,crisis in power supply,mining ban ,additional supply of PSU shares ..etc.etc.In mid and small caps space a real carnage is going on where stock prices of many companies ruling around life time or multi year lows.In addition to the above mentioned reasons , I believe one of the major factors affecting the sentiment in small/mid caps is the uncertainty created by the latest SEBI decision to change the trading method for illiquid stock.( not the method but the criteria for fixing the eligibility is the real reason for concern).It seems all market participants including stock exchange authorities,brokers and investors are in full of dark and no clue about the impact of this method on volume and price .I think ,this uncertainty is a major reason for the sharp fall in small/mid caps in past few weeks .There is no takers and hence no market depth for midcaps .Many of the investors are in a wait and watch mood and not ready to take any new commitments before some clarity emerges even they know the fact that many good companies are trading at attractive valuations.This is the feeling many of my friends shared in recent weeks .Some investors even selling their holdings and shifting their positions to other stocks which may excluded from new method based on the declared criteria. I believe ,SEBI is actually ‘burning the house to kill a rat’ .Let us wait one more week and see its implications.



This week’s recommendation is a low priced scrip which is not an illiquid stock under  new criteria !! .Reason  is not this alone but some more  positive developments happening in this company after a long period.MARKSANS PHARMA  is owned by Mr Mark Saldhana , the younger brother of the MD of Glenmark Pharma .Actually the name GLENMARK derived from the name of two brothers GLEN Saldhana and MARK Saldhana.In 2003 Glenmark Pharma’s wholly-owned subsidiary Glenmark Laboratories de-merged from it and later in 2005 this division merged with another listed company  Tasc Pharma .Then its name changed to the present one MARKSANS PHARMA and Mark Saldhana took charge of this company.Company’s performance was satisfactory till 2008 and thereafter  derailed due to different reasons.It raised FCCB for overseas buyouts and  took over some foregin companies in UK and Australia which did not perform initially, as expected.FCCB holders not converted their bonds  due to lower stock price and the repayment of the same ends as a huge burden on the company. As in the case of many other company’s issed FCCB’s during that period ,Indian currency’s diminishing valuation added fuel to fire.


 When we analyse in detail,it is clear that the two major reasons for huge loss in past many years  and complete erosion of net worth of this company is FCCB obligation and loss of its API division. Last year company exited from API and sold out this loss making unit.In a surprising announcement ( Read it HERE) ,in this month , company informed BSE  that it  has entered into a Settlement Agreement with the holders of Foreign Currency Convertible Bonds.Even the nature and means of this settlement not explained,MD's open market purchase of shares in the past few days indicating they have reached in a favorable settlement terms for  the company and some clear ideas in mind.Last year promoters subscribed preferential issue and hiked their stake to 51% from 48% .



After selling out its API division, company  now concentrating in Formulations,CRAMS and Bio pharmaceuticals . Oncology, Gastroenterology, Antidiabetic, Cardiovascular, Pain Management, and Gynecology  are selected as key areas of interest.Of late company’s Australian Subsidiary( Link HERE) is also started to perform . Since company’s foreign operations are bigger than Indian business ,true picture is not reflecting in its stand alone result.Its consolidated Sales was Rs.357 Cr where sales from India was just Rs.156 Cr in FY 2012. In the just preceding  two quarters,both Indian and foreign operations are showing significant improvement.
                   

                                                                                           This low priced scrip selected mainly because of four  reasons – Pedigree of promoter,Fair chance for a Settlement of FCCB with favorable and practical terms and conditions , Improved financial performance,promoter’s effort to increase stake through preferential issue and open market purchase.We know last year’ fantastic turn around of another big pharma company started only after a similar settlement of FCCB obligation.Let us wait and see what will happen for this one.Those willing to take extreme risk and enough patience may try it around CMP Rs.10.57/- .Stock listed both in NSE and BSE.

The scrip is showing consistant profit and sales increase. The current market capitalisation stands at Rs 407.27 crore.The company has reported a consolidated sales of Rs 161.38 crore and a Net Profit of Rs 20.53 crore for the quarter ended Sep 2013.


FCCB settlement is expected to be over by next quarter after which the company may show profit in the range of 40cr. and EPS of about 4.One can buy the stock with an time frame of three years with a target of 100+.

The company management includes Mark Saldanha - Chairman & Managing Director, B S Desai - Whole Time Director, S R Buddharaju - Director, Ajay S Joshi - Director, Naresh Balwant Wadhwa - Ind.& Non Exe.Director. 


Link to Company's UK Subsidiary HERE





Link to Company's Australian  Subsidiary HERE


Link to latest Annual Report HERE

Courtesy: Value Pick Blog




STOCK RECOMMENED AT 4 HAS REACHED A HIGH OF rs.21.25 a return of 531 % , company is delivering continous good result and is going to grow by greater pace in coming years. one can expect to get multifold returns from the stock.currently the stock is trading at Rs.17.65 and is in consolidating phase just like all the time after this stock do.once can expect 35 range before next result. FCCB settlement can be expected in next quater as Mr.Mark  has suggested to close the FCCB by feb.

BOX OFFICE COLLECTION

52 week High Stock in BSE

CLOSE TO 52 WEEKS LOW STOCKS IN BSE